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A lack of knowledge of the health and environmental risks associated with chemicals of concern 
(COCs) and also of their removal by advanced treatment processes, such as micro–filtration (MF) 20 
and reverse osmosis (RO), have been major barriers preventing establishment of large water 
recycling schemes. As part of a larger project monitoring over 300 COCs, iodinated x–ray contrast 
media compounds (ICM) were analysed in treated secondary wastewater intended for drinking 
purposes. ICM are the most widely administered intravascular pharmaceuticals and are known to 
persist in the aquatic environment. A direct injection liquid chromatography tandem mass 25 
spectrometry (DI–LC–MS/MS) method was used to monitor secondary treated wastewater from 
three major wastewater treatment plants in Perth, Western Australia. In addition, tertiary water 
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treated with MF and RO was analysed from a pilot plant that has been built as a first step in trialling 
the aquifer recharge. Results collected during 2007 demonstrate that MF/RO treatment is capable of 
removing ICM to below the analytical limits of detection, with average RO rejection calculated to 
be greater than 92%. A screening health risk assessment indicated negligible human risk at the 
concentrations observed in wastewater. 5 
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INTRODUCTION   10 
 
Iodinated x–ray contrast media (ICM) are the most widely administered intravascular 
pharmaceuticals, administered in very high doses (60–120 g) in radiographic procedures.[1] The 
ICM are considered safe and are widely used. Nevertheless, mild acute reactions such as nausea and 
pain in the area of injection have been reported in 15% of patients receiving ionic and 3% of the 15 
patients receiving non–ionic ICM. [2]  Skin reactions after ICM administration, [3] kidney toxicity 
and thyroid toxicity  in patients at risk have been also reported. [4] No studies have conducted on 
human health effects of ICM at chronic low exposure concentrations derived from food and water. 
However, environmental risk assessment at environmental concentrations in water (µg/L) indicates 
that the ratio between the predicted environmental concentration (PEC) and the predicted no–effect 20 
concentration (PNEC) is less than 0.0002. [5] 
The ICM are designed to be highly soluble (through amide, carboxylic and hydroxyl terminal 
groups which also mask the toxicity of the aromatic ring) and have low biodegradability. They are 
metabolically stable, and are almost completely excreted from the body via urine or faeces within a 
day of administration. [6] While they are considered non–toxic to humans and wildlife, [1, 5, 7] the 25 
persistence of ICM through conventional and activated sludge wastewater treatment plants 
(WWTP) is well documented. [7-10] In fact, conventional treatment plants are known to be 
“transparent” to compounds characterized by high solubility and the low biodegradability. 
Concentrations in the effluent from WWTP can be between 5–40 µg iodine/L, [8, 11, 12] particularly if 
the WWTP receive waste from hospitals or radiological clinics. The ICM also persist in the aquatic 5 
environment and may leach through the subsoil into groundwater aquifers. [11, 13] Studies have also 
reported µg/L level of ICM concentrations in both raw and treated drinking water. [14-16] 
Tertiary wastewater treatment is also often unable to efficiently remove ICM. Removal through 
ozonation is slow and incomplete [11, 17, 18] and, while oxidation via UV/H2O2 is more efficient, the 
ICM that was tested (iopromide, 1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-10 
methoxyacetamido)-1-N-methylbenzene-1,3-dicarboxamide) showed lower reactivity than any 
other pharmaceuticals. [19] Reverse osmosis (RO) alone appears to effectively remove adsorbable 
organic iodine (AOI) [11] and has also been demonstrated to efficiently remove five specific ICM 
compounds from secondary effluent. [20] 
 15 
A key initiative of the Western Australian State Water Strategy is 30% wastewater reuse by 2030. 
Groundwater provides about 60% of Perth’s drinking water and using highly treated wastewater 
water to recharge aquifers beneath the Swan Coastal Plain provides the potential to meet a major 
component of this goal. The Groundwater Replenishment Trial (GWRT) will inject 5 GL/year of 
recycled water treated by microfiltration (MF), reverse osmosis (RO) and UV into the Gnangara 20 
groundwater mound, with re–extraction for drinking water planned for the future. The GWRT will 
assess the feasibility of the treatment and reinjection technologies, as well as community acceptance 
of groundwater replenishment. Depending on the success of the trial, a full–scale scheme would 
provide 25–35 GL/y (GL=Gigalitre) of drinking water (10 % of Perth’s water supply) by 2015. A 
further environmental benefit of aquifer recharge is prevention of the decline in groundwater levels 25 
that might otherwise occur as a result of abstraction or decreased rainfall. In the lead up to the GWR 
Trial a three year project was conducted to undertake chemical and microbiological risk 
assessments, develop health based water quality guidelines, [21] and characterise the treated 
wastewater to be used in the trial. As part of the wastewater characterisation program, involving 
over 300 chemicals, a rapid method for ICM analysis using direct injection liquid chromatography 5 
tandem mass spectrometry (DI–LC–MS/MS) has been developed. [20] Results for eight ICM 
compounds (i.e. iohexol, iothalamic acid, ioxaglic acid, iomeprol, iopamidol, diatrizoic acid, 
iodipamide, and iopromide) in secondary wastewater from metropolitan WWTP in Perth, Western 
Australia are presented. In addition, samples were taken from the Beenyup Pilot Plant (BPP), a pilot 
tertiary treatment plant employing MF/RO that was built. 10 
 




Samples were collected in two separate sampling events. The aim of the first event was to compare 
ICM concentrations in secondary treated wastewater collected from the three major Perth 
metropolitan WWTPs: Beenyup (120 ML/day, ML=Megalitre), Subiaco (60 ML/day) and 
Woodman Point (160 ML/day). While differences exist between the three WWTPs, the treatment 
process at each plant is comparable. First, large material such as rags and plastics is removed 20 
through screening and inorganic grit is removed by settling. Primary treatment removes the majority 
of solids through sedimentation, while advanced secondary treatment uses an activated sludge 
process that consumes organic material through microbial action. The secondary wastewater is 
discharged to the ocean after final clarification. Samples at Beenyup and Subiaco WWTPs were 
collected from the final discharge to ocean, while Woodman Point effluent was sampled within 25 
Kwinana Water Reclamation Plant (KWRP), a full scale MF/RO plant that supply water (e.g. for 
cooling or to generate high pressure steam) to neighbouring industrial facilities.  
Composite samples (24 h) were collected using a refrigerated automated sampling unit on three 
days at Woodman Point and two days at Beenyup and Subiaco WWTPs over a four week period 
(24/05/2007 – 19/06/2007). In addition, field and trip blanks were collected on each day of 5 
sampling. Samples were preserved with 100 mg/L sodium azide, added as a solid to the amber glass 
sample bottles before sampling, and stored at 4 °C until analysis. 
In the second sampling event, samples were taken from Beenyup WWTP only on three consecutive 
days (25/09/07 – 27/09/07). Tertiary treated water samples were also taken after processing through 
the BPP. While this pilot plant provides water representative of that which will be produced by the 10 
GWR trial, it only receives about 140 kL/day of secondary effluent, and produces about 100 kL/day 
of MF/RO treated water. Sample compositing and preservation were identical to the first sampling 
event and field and trip blanks were also collected each day. 
 
Standards and Chemicals 15 
 
The eight ICM analysed in the study were iopromide (IOP) (1-N,3-N-bis(2,3-dihydroxypropyl)-
2,4,6-triiodo-5-(2-methoxyacetamido)-1-N-methylbenzene-1,3-dicarboxamide) (Bayer Schering 
Pharma AG, Berlin, Germany), iomeprol (IOM) (1-N,3-N-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-
N-methylacetamido)-2,4,6-triiodobenzene-1,3-dicarboxamide) (Bracco s.p.a., Milano, Italy), 20 
iohexol (IOX) (1-N,3-N-bis(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-
triiodobenzene-1,3-dicarboxamide), iopamidol (IOD) (1-N,3-N-bis(1,3-dihydroxypropan-2-yl)-5-
[(2S)-2-hydroxypropanamido]-2,4,6-triiodobenzene-1,3-dicarboxamide), iothalamic acid (ITA) (3-
acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid), amidotrizoic acid (DTZ) (3,5-
diacetamido-2,4,6-triiodobenzoic acid ), ioxaglic acid (IXA) (3-[(2-hydroxyethyl)carbamoyl]-2,4,6-25 
triiodo-5-(2-{[2,4,6-triiodo-3-(methylcarbamoyl)-5-(N-
methylacetamido)phenyl]formamido}acetamido)benzoic acid) and iodipamide (IDP) (3-[[6-(3-
carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid) (United States 
Pharmacopeia–USP, Maryland, USA). Methanol and acetonitrile (ChromAR HPLC grade) were 
purchased from Mallinckrodt (New Jersey, USA); ammonium formate (purity 99.995%) was 5 
purchased from Sigma–Aldrich (NSW, Australia); formic acid (purity 99%) was purchased from 
Ajax FineChem (NSW, Australia). The MQ water used was purified using an IBIS Technology Ion 
Exchange System followed by Elga Purelab Ultra System. Disposable syringe filters (Acrodisc®, 
0.45µm pore size, 25 mm diameter) were purchased from PALL Life Sciences (NY, USA).  
 10 
A working solution containing all eight ICM (0.1 µg/µL) was prepared freshly for each analytical 
run, and calibration solutions were prepared by serial dilution of this working solution. Calibration 
standards for post–RO water are prepared using MQ water, while calibration standards for 




The DI–LC–MS/MS method avoided sample pre–concentration and the only sample preparation 
required was filtering (Acrodisc® Syringe Filters 0.45µm) secondary treated wastewater samples 
prior to injection in the LC–MS system. All DI–LC–MS/MS measurements were performed using 20 
an Agilent 1100 HPLC system (Palo Alto, CA, USA) equipped with a solvent degasser unit, a 
quaternary pump and a 100 well–plate autosampler, coupled to a Micromass Quattro Ultima Triple 
Quadrupole instrument (Manchester, UK), fitted with an electrospray interface (ESI) that was 
operated in positive ion mode. The method has previously been described in full, [20] including 
validation data for both secondary treated wastewater and post–RO water. Quantitation of post–RO 25 
samples was performed using an external calibration curves built in MQ water. To correct for 
possible matrix effects, quantitation of secondary wastewater samples was performed using 
standard addition. 
 
Instrumental and/or laboratory contamination were also monitored by regular and methodical 5 
analysis of injector and procedural blanks, as well as field and trip blanks collected during 
sampling. About 33% of total samples analysed were blanks (i.e. trip blanks, procedural blanks and 
field blanks). The needle of the injector was also rinsed thoroughly before and after each injection 
to minimise potential carryover. On average after every 100 injections, the guard column was 
replaced, the analytical column back–flushed with acetonitrile for 60 min, and the mass 10 
spectrometer thoroughly cleaned to ensure consistent system performance. 
 
Limits of detection (LODs), calculated from the concentration equivalent to a signal to noise ratio 
(S/N) of three, ranged between 0.10 (IXA) and 0.58 (ITA) µg/L in post–RO water and between 0.11 
(IXA, IDP) and 0.97 µg/L (ITA) in secondary effluent. These LODs enabled easy detection of ICM 15 




Comparison of ICM in Perth WWTPs 20 
 
Comparison of ICM concentrations in secondary effluent from Perth’s three major WWTPs is 
shown in Figure 1. The data is presented as average concentrations (µg/L) in samples collected on 
three days at Woodman Point and two days at Beenyup and Subiaco WWTPs over a four week 
period (24/05/2007 – 19/06/2007). Data from field and trip blanks are not included, as all results for 25 
these samples were below LOQ. 
 
Iothalamic acid, ioxaglic acid and iomeprol were always lower than the LOQ, while diatrizoic acid 
was detected only once above LOQ (Woodman point WWTP). Iopamidol, iohexol, iodipamide, and 
iopromide were always above LOQ, ranging between 0.2–10 µg/L. While Subiaco WWTP showed 5 
the highest average concentrations of ICM compared to Woodman Point or Beenyup WWTP, the 
results were influenced by the exceptionally high concentrations of iopamidol, iohexol and 
iopromide measured on one day (12/06/07). This may indicate that ICM concentrations can vary 
within WWTP, related to diurnal variations in discharge within the catchment (i.e. flow rate and 
quality of the WWTP influent). Additional sampling is required to determine the normal magnitude 10 
of variation. Radiological examinations in Perth are carried out at small metropolitan clinics that are 
evenly distributed over each of the three WWTP catchments, as well as at major hospitals, so it is 
not unexpected that ICM concentrations are similar at all three WWTP. The ICM showing the 
highest concentrations was iohexol, which averaged between 4–10 µg/L, confirming that the most 
commonly used ICM in Western Australia was probably Omnipaque 350, a commercial preparation 15 
of iohexol. Other commonly used iodinated contrast media include Ultravist 300 (iopromide) and 
Iopamiro 370 (iopamidol), [22] which were also simultaneously detected in all the samples analysed 
in this work. Despite being detected, concentrations measured in secondary treated wastewater were 
still two to three orders of magnitude lower than those ICM included Australian Guidelines for 
Water Recycling (Phase 2) [23] (iohexol, iopamidol and iopromide) and lower than ICM 20 
concentrations previously reported in European WWTP. [14-16] 
 
Concentration of ICM at BPP 
 
Results from pre–RO (post–MF) water from three consecutive days at BPP are presented in Figure 25 
2. Three ICM were consistently above LOQ in the wastewater – iodipamide (0.7–0.9 µg/L), iohexol 
(2.3–7.4 µg/L), and iopromide (1.4–2.8 µg/L), while diatrizoic acid was measured above LOQ on 
two days (1.4–2.5 µg/L). Considering the detection of iopamidol in the first sampling event (Fig. 2), 
only iothalamic acid, iomeprol and ioxaglic acid were not measured above LOQ at Beenyup. Again, 
data from field and trip blanks were below LOQ and concentrations measured in the secondary 5 
effluent were still two to three orders of magnitude lower than the health guidelines values. 
 
The concentration of ICM in post–RO water from the Beenyup Pilot Plant was always below LOQ 
and this is consistent with measurements previously presented for the KWRP [20], which also uses 
MF/RO to produce high quality process water for industrial use. The non–detection of any ICM in 10 
post–RO water samples is attributed to the high molecular weight of the ICM, promoting RO 
membrane rejection of the compounds. Together the results from BPP and KWRP confirm the 





A literature survey to determine ICM concentrations reported globally has demonstrated that there 
are very few studies of ICM that have been published outside of Germany (Table 1).  In this 
context, the results from our study are a valuable addition to the global knowledge base of ICM in 20 
secondary wastewater as well as in post–RO treated water. The ICM concentrations we found in 
secondary wastewater in this study are similar to those reported in other WWTPs, suggesting that 
dosage and ICMs prescribed are consistent and further confirming that conventional wastewater 
treatment plants do not effectively remove ICM from raw influent wastewater.  
Removal efficiencies for RO can only be estimated from our data because all the compounds were 25 
below detection in post–RO water. However, if we use an upper bound of half the post–RO water 
LOD, average RO removal efficiencies from the Beenyup Pilot Plant were (± relative standard 
deviation, usually n = 3): diatrizoic acid 92±3%; iodipamide 94±1%; iohexol 95±2%; iopromide 
95±2%. We can compare this RO removal efficiencies calculated using data previously reported for 
Kwinana Water Reclamation Plant (KWRP), [20] where efficiencies were: diatrizoic acid 96±1%; 5 
iodipamide 92±3%; iohexol 95±1%; iopromide 97±1%; iopamidol 97±1%. Removal efficiency was 
not calculated for those ICMs present in wastewater at concentrations lower than the secondary 
wastewater LOQ or only slightly greater than the post–RO water LOQ (e.g. iopamidol at Beenyup 
WWTP and iothalamic acid, ioxaglic acids and iomeprol at both Beenyup and Woodman Point 
WWTPs). Spiking experiments would be necessary to estimate the actual removal efficiency of the 10 
RO treatment, similar to studies already carried out for nanofiltration and microfiltration. [24, 25] 
Despite differences in plant size and water use, removal efficiencies for the BPP and KWRP were 
very similar. Literature concerning removal of ICM by RO plants is very scarce, by our estimated 
removal efficiencies also compare very well to the estimated removal efficiency of > 90% for 
iopromide in virgin RO membranes by Snyder and others, [24, 26] and 97% removal efficiency of 15 
AOI. [11] To the best of our knowledge, no other studies reporting removal of ICMs by RO plants 
have been published to date. The high rejection efficiencies observed at the advanced treatment 
plants were expected on the basis of the high MW of the compounds (600–1300 Da) compared the 
nominal molecular weight cut–off of the membranes (100–150 Da). [27, 28] Other parameters that 
play an important role in the rejection mechanisms include compound–specific physico–chemical 20 
properties, such as solubility, diffusivity, polarity, hydrophobicity, pKa, and specific membrane 
properties (e.g., permeability, pore size, hydrophobicity, and charge), as well as membrane 
operating conditions (e.g., flux, transmembrane pressure, and regeneration). However, studies of 
iopromide rejection by microfiltration and nanofiltration have significantly lower removal 
efficiencies, of <25% and 58% respectively, [25] which indicates size exclusion is the major factor 
influencing removal. 
 
Because not all the ICM measured in this study are in the AGWR, [23] health values were also 
calculated using the lowest therapeutic dose from the pharmacopeia (Table 2). The lowest 5 
therapeutic dose [23] of each ICM was multiplied by the proportion of the contaminant in water 
compared to other exposure pathways, assumed to be 90%. A safety factor of 1000 was used to 
derive the health value (10 for intra–species variability; 10 for using the lowest therapeutic dose 
instead of the non–observed effect concentration; and 10 for protection of sensitive population 
subgroups including children and infants). Risk Quotients (RQ) were calculated as the ratio between 10 
the maximum reported concentration of each ICM in secondary wastewater and the corresponding 
health based value (Table 2). For those ICM not detected, the RQ reported was calculated using the 
average LOQ achieved for the analyte.  In secondary effluent, all RQs were 1 to 3 orders of 
magnitude below 1, even when the maximum concentration was used to calculate the ratio. These 
results indicate that a very low human risk is anticipated at the concentrations of ICM observed in 15 
secondary effluent.  Furthermore, in our study ICMs in post–RO water were always lower than 
LOQ (<0.1–0.58 µg/L) thus 2  to 4 orders of magnitude lower than the health based values. These 
risk estimates agree with the I70 (lifetime intake based on 2L/day water consumption over 70 years) 
calculated from drinking water intake for a range of ICM used in Germany (i.e. iopamidol, 
iopromide, ioxaglic acid iothalamic acid and diatrizoic acid). [30] For these compounds I70 was 20 
between 5 × 102 and 4 × 103 µg, which is 4 to 5 orders of magnitude lower than a single therapeutic 




Comparison of ICM in different WWTP showed that average ICM concentration ranged between 1 
and 10 µg/L. Iohexol showed the highest average concentrations, up to 10.8 µg/L, while 
concentrations of the other ICM ranged between 0.1 and 5 µg/L. Iothalamic acid, ioxaglic acid and 
iomeprol were always lower than the LOQ. Following on from our initial study, [20] the results 
presented here further confirm that RO is an effective treatment to remove iopamidol, diatrizoic 5 
acid, iodipamide, iohexol, and iopromide to below LOQ. The non–detection of any ICM in post–
RO treated water samples was attributed to the high molecular weight of the ICM, promoting RO 
membrane rejection of the compounds, with rejection consistently greater than 92%. While several 
ICM were measured in secondary treated wastewater, all concentrations were one to three orders of 
magnitude lower than health based values. Concentrations of ICM in post–RO water were always 10 
lower than LOQ (<0.1–0.58 µg/L) thus 2 to 4 orders of magnitude lower than the health based 
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Figure 1. ICM concentrations in wastewater samples collected from three Perth metropolitan 
WWTPs: Subiaco, Woodman Point, and Beenyup WWTP. LOQs for secondary wastewater are also 
reported for comparison. All data from field and trip blanks were below LOQs and therefore not 5 
included. 
 
Figure 2. ICM concentration in pre–RO samples collected from the BPP, Perth WA. LOQs for both 
wastewater and RO water are also plotted. All data from field and trip blanks and post–RO samples 












Table 1: Concentration of X–ray contrast media in secondary effluent and post–RO samples from 
various water treatment facilities. RO rejection is also reported.  
 




(%) Country Reference 
4.1 n.a. n.a. Germany [9] 
1.1 n.a. n.a. Germany [29] 
15 n.a. n.a. Germany [12] 
5.7 n.a. n.a. Germany [18] 
0.9–4.90 < 0.4 > 96±1 Australia [20] 
Diatrizoic 
acid 
<1–2.5 < 0.3 > 92±3 Australia This study 
0.14 n.a. n.a. Germany [9] 
0.09 n.a. n.a. Germany [29] 
< 0.7 < 0.6 n.a. Australia [20] 
Iothalamic 
acid 
< 0.9 < 0.3 n.a. Australia This study 
4.7 n/a n.a. Germany [9] 
0.59 n/a n.a. Germany [29] 
1.1 n/a n.a. Germany [18] 
0.4–0.62 < 0.2 > 97±1 Australia [20] 
Iopamidol 
< 0.2 < 0.2 n.a. Australia This study 
9.3 n.a. n.a. Spain [8] 
8.1 n.a. n.a. Germany [9] 
3.1 n.a. n.a. Germany [29] 
21 n.a. n.a. Germany [12] 
5.2 n.a. n.a. Germany [18] 
Iopromide 
0.165 < 0.025 > 92* USA [24] 
0.125 0.072 > 42** USA [24] 
0.43–1.35 < 0.2 > 97±1 Australia [20] 
 
1.4–2.8 < 0.2 96±2 Australia This study 
1.3 n.a. n.a. Germany [9] 
2.06 n.a. n.a. Germany [29] 
2.3 n.a. n.a. Germany [18] 
< 0.7 < 0.2 n.a. Australia [20] 
Iomeprol 
< 0.8 < 0.2 n.a. Australia This study 
7 n.a. n.a. Germany [12] 
2.80–4.76 < 0.2 95±1 Australia [20] Iohexol 
< 0.5 < 0. 3 n.a. Australia This study 
0.14–0.23 < 0.1 92±3 Australia [20] Iodipamide 0.7–0.9 < 0.1 94±1 Australia This study 
< 0.3 < 0.1 n.a. Australia [20] Ioxaglic 
acid < 0.3 < 0.1 n.a. Australia This study 
*RO rejection using virgin membranes; ** RO rejection using fouled membranes 
 
Table 2: ICM guideline limits and Risk Quotients calculated using the maximum reported 
concentration of each ICM in secondary wastewater.  
 5 
Compound Health based value (µg/L) Risk Quotient 
Diatrizoic acid 360 0.04 
Iothalamic acid 350 0.0004 
Iopamidol 360 0.01 
Iopromide 680 0.03 
Iomeprol 810 0.003 
Iohexol 650 0.01 
Iodipamide 540 0.002 
Ioxaglic acid 350 0.009 
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